EGFR and myelodysplastic syndrome: Furthermore, the combination of azacytidine (a chemotherapeutic agent) and erlotinib (an inhibitor of the epidermal growth factor receptor) has a synergetic effect in acute myeloid leukemia (AML) cells and primary AML, and myelodysplastic syndrome (MDS) cells by inducing proteasomal degradation of Mcl-1 and Bcl-B; these data indicate the indirect inhibition of Bcl-B [61].